首頁 > 市場調查報告書 > 製藥

癌症呼吸器

2030 年北美肺癌治療市場預測 - 區域分析 - 按治療類型、適應症和最終用戶

市場調查報告書

商品編碼

1494400

2030 年北美肺癌治療市場預測 - 區域分析 - 按治療類型、適應症和最終用戶

North America Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

出版日期: 2024年03月14日 | 出版商:

The Insight Partners | 英文 79 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年北美肺癌治療市值為151.0592億美元，預計2030年將達385.5655億美元；預計2022年至2030年複合年成長率為12.4%。

肺癌病例的增加推動北美肺癌治療市場

肺癌是全世界死亡的主要原因之一。如果及早診斷，這種類型的癌症可以得到更有效的治療。因此，肺癌高風險族群需要接受常規檢查，以檢測肺部癌變的形成。在全球範圍內，肺癌是男性最常見的癌症，也是女性第二常見的癌症。根據世界衛生組織 (WHO) 的數據，肺癌是全球男性和女性癌症相關死亡的主要原因。根據世界癌症研究基金會的數據，2020 年全球新增肺癌病例約 220 萬例。名。根據加拿大癌症協會估計，預計將有 31,000 名加拿大人被診斷出患有肺癌和支氣管癌。這將佔 2023 年所有新癌症病例的 13%。在 2023 年所有癌症相關死亡中，這一比例佔 24%。因此，全球肺癌發生率的上升促進了肺癌治療的研發活動，進而推動了市場的成長。

北美肺癌治療市場概況

美國北美肺癌治療市場的成長主要是由肺癌病例發生率上升、產品發布和政府措施推動的。肺癌是美國第二常見癌症。根據美國癌症協會的數據，截至 2023 年，美國約有 238,340 名成年人（117,550 名男性和 120,790 名女性）被診斷出患有肺癌；此外，約有 127,070 人（男性 67,160 人，女性 59,910 人）死於此疾病。肺癌佔所有癌症死亡的五分之一，使其成為美國癌症死亡的主要原因。根據同一來源，非小細胞肺癌 (NSCLC) 佔所有肺癌診斷的 81%。因此，該國肺癌發病率的上升推動了美國肺癌治療市場的成長。

公司推出的各種治療肺癌的產品也促進了市場的成長。例如，2021年5月，美國FDA核准Lumakras（sotorasib）作為第一個針對成人非小細胞肺癌患者的標靶治療藥物。這是第一個被批准用於具有 KRAS 突變的腫瘤的標靶治療，據報告，非小細胞肺癌 (NSCLC) 中約有 25% 的突變。此外，2021年5月，美國FDA加速核准amivantamab-vmjw (Rybrevant)，是一種針對錶皮生長因子(EGF)和MET受體的雙特異性抗體，用於治療含有EGFR外顯子20插入的局部晚期或轉移性NSCLC成人患者突變。

根據數位策略辦公室管理的白宮官方網站 Whitehouse.gov 於 2023 年 5 月發布的報告，社區癌症中心協會 (ACCC) 與阿斯特捷利康建立了合作夥伴關係，以開發和實施透過「農村阿巴拉契亞肺癌篩檢計畫”，以人為本和永續的方法來推動美國農村地區的肺癌篩檢。阿巴拉契亞地區（包括整個西維吉尼亞州和其他 12 個州的部分地區）的癌症死亡率比美國其他地區高 10%。該措施旨在將肺癌的五年存活率提高一倍。這些措施正在促進美國北美肺癌治療市場的成長。

北美肺癌治療市場收入及 2030 年預測（百萬美元）

北美肺癌治療市場細分

北美肺癌治療市場根據治療類型、適應症、最終用戶和國家進行細分。

根據治療類型，北美肺癌治療市場分為非侵入性治療和微創治療。到2022年，非侵入性細分市場將佔更大佔有率。

有跡象表明，北美肺癌治療市場分為非小細胞肺癌和小細胞肺癌。 2022 年，非小細胞肺癌細分市場將佔據更大佔有率。

依最終用戶分類，北美肺癌治療市場分為醫院、腫瘤診所、研究中心等。 2022 年，醫院領域佔最大佔有率。

按國家/地區分類，北美肺癌治療市場分為美國、加拿大和墨西哥。 2022年，美國將主導北美肺癌治療市場。

Medtronic Plc、RF Medical Co Ltd、Johnson & Johnson、Merck KGaA、Sun Pharmaceutical Industries Ltd、Bioventus Inc、Olympus Corp、Meiji Seika Pharma Co Ltd 和 Advanz Pharma Corp 是北美肺癌治療領域的一些領先公司市場。

Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020. According to the American Cancer Society's estimates for lung cancer in the US, ~238,340 new lung cancer cases are likely to be registered in 2023, including 120,790 women and 117,550 men. According to estimates from the Canadian Cancer Society, 31,000 Canadians are expected to be diagnosed with lung and bronchus cancer. This will represent 13% of all new cancer cases in 2023. In addition, lung and bronchus cancer will result in the death of 20,600 Canadian citizens. Of all cancer-related deaths in 2023, this accounts for 24%. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.

North America Lung Cancer Therapy Market Overview

The growth of the North America lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.

Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.

As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through "Rural Appalachian Lung Cancer Screening Initiative." The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the North America lung cancer therapy market in the US.

North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

North America Lung Cancer Therapy Market Segmentation

The North America lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the North America lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the North America lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the North America lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the North America lung cancer therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the North America lung cancer therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 North America Lung Cancer Therapy Market, by Country

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Lung Cancer Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Increase in Cases of Lung Cancer
- 4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
- 4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
- 4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
- 4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:

5. Lung Cancer Therapy Market - North America Market Analysis

5.1 North America Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

6. North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

6.1 Overview
6.2 North America Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
- 6.3.1 Overview
- 6.3.2 Non-Invasive Therapy: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
- 6.4.1 Overview
- 6.4.2 Minimally Invasive: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.3 North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

7. North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

7.1 Overview
7.2 North America Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 North America Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
- 8.4.1 Overview
- 8.4.2 Oncology Clinics: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
- 8.5.1 Overview
- 8.5.2 Research Centers: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Lung Cancer Therapy Market - Country Analysis

9.1.1 North America North America Lung Cancer Therapy Market, by Country
- 9.1.1.1 US
  - 9.1.1.1.1 Overview
  - 9.1.1.1.2 US: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.1.3 US: North America Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.1.3.1 US: North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.1.4 US: North America Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.1.5 US: North America Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.2 Canada
  - 9.1.1.2.1 Overview
  - 9.1.1.2.2 Canada: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.2.3 Canada: North America Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.2.3.1 Canada: North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.2.4 Canada: North America Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.2.5 Canada: North America Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.3 Mexico
  - 9.1.1.3.1 Overview
  - 9.1.1.3.2 Mexico: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.3.3 Mexico: North America Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.3.3.1 Mexico: North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.3.4 Mexico: North America Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.3.5 Mexico: North America Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

10. Lung Cancer Therapy Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in North America Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 RF Medical Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck KGaA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bioventus Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Olympus Corp
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Advanz Pharma Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America Lung Cancer Therapy Market Segmentation
Table 2. North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. US North America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada: North America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico: North America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico: North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico: North America Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 15. Recent Inorganic Growth Strategies in the North America Lung Cancer Therapy Market
Table 16. Recent Organic Growth Strategies in North America Lung Cancer Therapy Market
Table 17. Glossary of Terms, North America Lung Cancer Therapy Market

List Of Figures

Figure 1. North America Lung Cancer Therapy Market Segmentation, By Country
Figure 2. North America Lung Cancer Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030
Figure 5. North America Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 6. Non-Invasive Therapy: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Minimally Invasive: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. North America Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 9. Non-Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. North America Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 12. Hospitals: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Oncology Clinics: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Research Centers: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: North America Lung Cancer Therapy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 17. North America North America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 18. US: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Canada: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Mexico: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Growth Strategies in North America Lung Cancer Therapy Market